UPenn

KEI Request Re: Failure to Disclose Federal Funding in UPenn Bennett et al Patents for Gene Therapy to Treat Blindness

Posted on by Claire Cassedy

On September 9, 2019, KEI submitted a second request to the NIH that it investigate an apparent failure to disclose federal funding in patents in adeno-associated viral (AAV) gene therapies assigned to the Trustees of the University of Pennsylvania (UPenn).… Continue Reading →

UPenn, Nationwide Children’s Hospital refuse to disclose which patents they licensed to Novartis for Zolgensma

Posted on by Laurel Boman

Zolgensma, Novartis’s new $2.1 million gene therapy for children with spinal muscular atrophy (SMA), is a remarkable breakthrough with a steep price tag: the cost per child is $2.125 million. The treatment was developed using research funded by the National… Continue Reading →